Update on antiarrhythmic drug pharmacology
Update on antiarrhythmic drug pharmacology
复制标题
抗心律失常药物药理学最新进展
DOI：
10.1111/jce.14347
复制
发表时间：
2020-01
影响因子：
2.7
通讯作者：
Lei Ming
中科院分区：
文献类型：
--
作者：
Huang Christopher L. -H.;Wu Lin;Jeevaratnam Kamalan;Lei Ming
心律失常是一个重大的公共卫生问题。药物干预仍然是他们临床治疗的主要手段。这反过来又取决于系统的药物分类方案，该方案将其分子、细胞和系统效应与临床适应症和治疗行动联系起来。这种方法最早是在20世纪60年代的沃恩-威廉姆斯分类中提出的。随后在心脏电生理理解方面的进展导致了基础科学和临床翻译之间的滞后，欧洲心脏病学会工作组(1991)部分解决了这一问题，然而，这并没有出现正式的分类。在这里，我们利用最近修订的牛津分类方案来回顾抗心律失常药物的药理学。我们综述了最近表征的离子通道、转运体、受体、细胞内钙处理和细胞信号分子提供的药物和治疗靶点。这些都被组织成它们在心脏电生理功能中的战略角色。在对心律失常过程本身进行分析之后，我们考虑：(A)直接针对膜功能的药物，特别是心脏动作电位去极化和复极化事件背后的Na+和K+离子通道。(B)我们还考虑了改变自主神经活动的药物，进而影响膜和(C)将膜兴奋与收缩激活联系在一起的钙离子稳态和兴奋-收缩耦合过程。最后，我们认为(D)作用于更上游能量和结构重建过程的药物目前是临床试验的主题。这种在不同分子水平的药物作用和心律失常机制与心脏功能的系统水平的系统相关性将有助于当前和未来的抗心律失常治疗。
Cardiac arrhythmias constitute a major public health problem. Pharmacological intervention remains mainstay to their clinical management. This, in turn, depends upon systematic drug classification schemes relating their molecular, cellular, and systems effects to clinical indications and therapeutic actions. This approach was first pioneered in the 1960s Vaughan‐Williams classification. Subsequent progress in cardiac electrophysiological understanding led to a lag between the fundamental science and its clinical translation, partly addressed by The working group of the European Society of Cardiology (1991), which, however, did not emerge with formal classifications. We here utilize the recent Revised Oxford Classification Scheme to review antiarrhythmic drug pharmacology. We survey drugs and therapeutic targets offered by the more recently characterized ion channels, transporters, receptors, intracellular Ca2+ handling, and cell signaling molecules. These are organized into their strategic roles in cardiac electrophysiological function. Following analysis of the arrhythmic process itself, we consider (a) pharmacological agents directly targeting membrane function, particularly the Na+ and K+ ion channels underlying depolarizing and repolarizing events in the cardiac action potential. (b) We also consider agents that modify autonomic activity that, in turn, affects both the membrane and (c) the Ca2+ homeostatic and excitation‐contraction coupling processes linking membrane excitation to contractile activation. Finally, we consider (d) drugs acting on more upstream energetic and structural remodeling processes currently the subject of clinical trials. Such systematic correlations of drug actions and arrhythmic mechanisms at different molecular to systems levels of cardiac function will facilitate current and future antiarrhythmic therapy.
登录
查看更多内容
影响因子：
4
作者：
Wang Y;Tsui H;Bolton EL;Wang X;Huang CL;Solaro RJ;Ke Y;Lei M
通讯作者：
Lei M
影响因子：
--
作者：
Antzelevitch C;Burashnikov A
通讯作者：
Burashnikov A
DOI：
10.1016/b0-7216-0323-8/50105-6
发表时间：
2004
期刊：
--
影响因子：
--
作者：
J. Dimarco
通讯作者：
J. Dimarco
DOI：
10.1016/s0021-9258(18)68422-4
发表时间：
1988-06
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
M. Fosset;J. R. Weille;R. D. Green;H. Schmid-Antomarchi;M. Lazdunski
通讯作者：
M. Fosset;J. R. Weille;R. D. Green;H. Schmid-Antomarchi;M. Lazdunski
影响因子：
37.8
作者：
Liu W;Zi M;Naumann R;Ulm S;Jin J;Taglieri DM;Prehar S;Gui J;Tsui H;Xiao RP;Neyses L;Solaro RJ;Ke Y;Cartwright EJ;Lei M;Wang X
通讯作者：
Wang X